Submissions from 2024
Dermatology personal statement themes and match outcomes, Redina Bardhi, L. Bugosh, M. Al-Hadidi, J. Duong, S. Colbert, B. Jones, and S. Daveluy
Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2-11 years: 52 week results from a maximum-use trial, Robert Bissonnette, Mark S. Lee, Seth B. Forman, Linda F. Stein Gold, Howard Kallender, Brett Angel, Yutzu Kuo, and Amy S. Paller
Tapinarof cream 1% once daily: Interim analysis of ADORING 3 phase 3 long-term extension trial in adults and children down to age 2 years with atopic dermatitis, Robert Bissonnette, Linda F. Stein Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis, Christopher G. Bunick, Neal Bhatia, James Del Rosso, Zoe D. Draelos, Lawrence F. Eichenfield, Leon H. Kircik, Mark G. Lebwohl, Melinda Gooderham, Lawrence J. Green, Adelaide A. Hebert, Ronald B. Vender, Matthew Zirwas, Eric L. Simpson, Linda F. Stein Gold, Melissa Seal, Scott Snyder, David W. Osborne, Patrick Burnett, Robert C. Higham, David H. Chu, and David R. Berk
Global survey reveals demand for additional photoprotection education in Australia...Cancer Nurses Society of Australia (CNSA) 26th Annual Congress, June 19-21, 2024, Brisbane, Queensland, L. Dousset, K. Khosrotehrani, P. Guitera, T. Passeron, B. Dreno, Henry W. Lim, D. Kerob, and J. Krutmann
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study, Lawrence F. Eichenfield, April W. Armstrong, Linda F. Stein Gold, Andrea L. Zaenglein, Lara Wine Lee, Kanwaljit K. Brar, Joel C. Joyce, Kristen E. Holland, Brett Angel, Daniel Sturm, Qian Li, and Eric L. Simpson
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study, Melinda J. Gooderham, Stephan Weidinger, Eric L. Simpson, Mette Deleuran, Linda F. Stein Gold, Saleem A. Farooqui, Pinaki Biswas, Gary Chan, Erman Güler, and Herwig Koppensteiner
Environment impacts the phenotypic severity of flaky tail, MC903-induced inflammation, and dysbiosis in filaggrin-null mice, Autumn Hicks, Mohammed H. M Bharmal, A. Schmidt, Q Zheng, Congcong Yin, Peter Dimitrion, Qing-Shing Mi, Emelia Grice, Indra Adrianto, and Cristina de Guzman Strong
Transforming Growth Factor β-activated Kinase 1 Controls Langerhans Cell Homeostasis through Autophagic Machinery, Nirmal Parajuli, Q. Wang, Q. Yu, James Ge, Qing-Shing Mi, and Li Zhou
Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo, Thierry Passeron, Khaled Ezzedine, Iltefat H. Hamzavi, Nanja van Geel, Bethanee J. Schlosser, Xiaofei Hu, Xiaohong Huang, David Rosmarin, John E. Harris, Heidi S. Camp, and Amit G. Pandya
Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies, Vimal H. Prajapati, Christopher G. Bunick, Kilian Eyerich, Linda F. Stein Gold, Fabrizio Galimberti, Brian Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Cristina Sancho, Ayman Grada, and Alan D. Irvine
Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up), Jonathan I. Silverberg, Christopher Bunick, H. Chih-ho Hong, Pedro Mendes-Bastos, Linda F. Stein Gold, Antonio Costanzo, Nadia Ibrahim, Cristina Sancho, Xiaoqiang Wu, Yu Han, Gweneth Levy, Kathy Altman, and Kilian Eyerich
Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age, Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda F. Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna M. Tallman, and Leon Kircik
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results, Jonathan I. Silverberg, Emma Guttman-Yassky, Eric L. Simpson, Kim A. Papp, Andrew Blauvelt, Chia-Yu Chu, H. Chih-ho Hong, Linda F. Stein Gold, Thomas Bieber, Kenji Kabashima, David Rosmarin, Amy Gamelli, Brian Calimlim, Namita Vigna, Xiaofei Hu, Yang Yang, Xiaoqiang Wu, Xiaohong Huang, Smitha Suravaram, Henrique D. Teixeira, Eliza Raymundo, and Alan D. Irvine
A novel efficacy index for long-term therapy outcomes expressed by maintenance of EASI 75 and IGA 0,1 response in atopic dermatitis, Jonathan I. Silverberg, Alan Irvine, Peter Foley, James Del Rosso, Alexander Schacht, Martin Dossenbach, Marta Casillas, Erin Johansson, Gaia Gallo, and Linda F. Stein Gold
Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data, Jonathan I. Silverberg, Linda F. Stein Gold, Diamant Thaçi, Andrew E. Pink, Kim A. Papp, Franz J. Legat, Vivian T. Laquer, Soo Yeon Cheong, Liliana Ulianov, Anna Ryzhkova, and Christophe Piketty
Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry, Eric Simpson, Christian Fenske, Alvin Li, Zach Dawson, Yolanda Muñoz Maldonado, Kaylee Ho, Kayla Callahan, Linda F. Stein Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, and Jonathan I. Silverberg
Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis, Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda F. Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman, and Lawrence F. Eichenfield
Identifying disparities in phototherapy dosing and research participation among patients with psoriasis by race, ethnicity, and skin phototype: Findings from the light treatment effectiveness study, W. B. Song, B. Bishop, R. Fitzsimmons, A. Bridges, U. Nehal, D. Shin, Henry W. Lim, J. Takeshita, L. Howard, K. Duffin, and J. Gelfand
Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY, Linda F. Stein Gold, Stephan Weidinger, Delphine Staumont-Salle, Saeko Nakajima, Eric L. Simpson, Marjolein de Bruin Weller, Sonya Davey, Kassim Rahawi, and Charlotte Bernigaud
REAL WORLD EFFECTIVENESS OF INITIATING TOPICAL THERAPY COMPARED WITH INITIATING APREMILAST EARLY OR LATE, Bruce Strober, Linda F. Stein Gold, Paolo Gisondi, Kate Orroth, Myriam Cordey, Shia T. Kent, Cynthia Deignan, Shauna Jardon, Rohini K. Hernandez, M. Alan Brookhart, and April Armstrong
DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS, B. Strober, H. Sofen, S. Imafuku, C. Paul, M. Gooderham, L. Spelman, S. J. Seo, T. Passeron, R. M. Kisa, V. Berger, E. Vritzali, K. Hoyt, M. J. Colombo, S. Banerjee, M. Augustin, Linda F. Stein Gold, A. Alexis, D. Thaçi, A. Blauvelt, and M. Lebwohl
Spitz-Type Proliferative Nodule With Novel LMNA-RAF1 Fusion Arising Within a Large Congenital Melanocytic Nevus, Gautham Vellaichamy and Ben Friedman
CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa, Ping Wang, Peter Dimitrion, Albert Young, Congcong Yin, Iltefat H. Hamzavi, Indra Adrianto, Li Zhou, and Qing-Shing Mi
Response to ritlecitinib with or without narrow band ultraviolet B (nbUVB) add-on therapy in patients with active non-segmental vitiligo (NSV), Yuji Yamaguchi, Elena Peeva, Roni Adiri, Pranab Ghosh, Lynne Napatalung, Iltefat H. Hamzavi, Amit G. Pandya, Ronald N. Shore, Khaled Ezzedine, and Emma Guttman-Yassky
Conjunctivitis adverse events in dupilumab clinical trials, Matthew Zirwas, Raj Chovatiya, Linda F. Stein Gold, Brad Shumel, Amy Praestgaard, Zhen Chen, Tayler Gonzalez, Guy Gherardi, and Emma Lawless
Submissions from 2023
HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes, Peter Dimitrion, Jugmohit Toor, James Ge, Qiyan Wang, Carl E. Allen, Li Zhou, and Qing-Sheng Mi
CO125 Efficacy of Clascoterone Cream 1% for up to 12 Months in Patients ≥9 Years of Age with Acne vulgaris: Results from a Long-Term Extension Study, Lawrence F. Eichenfield, Adeaide A. Hebert, Linda F. Stein Gold, Martina Cartwright, L. Moro, J. Han, Nicholas Squittieri, and A. Mazzetti
Efficacy and Safety of Clascoterone Cream 1% in Patients with Acne vulgaris across Subgroups Defined By Demographic Characteristics, Lawrence F. Eichenfield, Adelaide A. Hebert, Linda F. Stein Gold, Martina Cartwright, L. Moro, J. Han, Nicholas Squittieri, and A. Mazzetti
42299 Long-term safety and efficacy of 1% clascoterone cream in patients <12 years old with acne>vulgaris, Lawrence F. Eichenfield, Adelaide A. Hebert, Linda F. Stein Gold, Martina Cartwright, Luigi Moro, Jenny Han, Nicholas Squittieri, and Alessandro Mazzetti
42445 Eruptive Keratoacanthoma of Grzybowski in an African American Female, Kareem Elhage, Michael Kwa, and Henry W. Lim
Impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among patients with moderateto- severe non-nodular acne vulgaris (AV) administered sarecycline in real-world community practices across the US (PROSES Study), Richard G. Fried, Evan A. Rieder, Andrew F. Alexis, Hilary Baldwin, Emmy Graber, Julie C. Harper, Linda F. Stein Gold, Adelaide Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, and Ismail Kasujee
42099 Analysis of utilization of sun-protective behavior among national SPOT Skin Cancer® program screenees from 2018 to 2019, David Gao, Susan Swetter, Elena W. Hawryluk, Alan Geller, and Derek Beaulieu
43405 Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations, Mahmoud Ghannoum, Ahmed Gamal, Ahmed Kadry, James Q. Del Rosso, Christopher Bunick, Linda F. Stein Gold, Leon Kircik, and Julie Harper
43390 Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants, Melinda Gooderham, Eric Simpson, Bob Geng, Linda F. Stein Gold, Andreas Wollenberg, Saleem A. Farooqui, Fan Zhang, and Claire Feeney
44222 Primary Cutaneous Adenoid Cystic Carcinoma: Report of a Rare Tumor with Review of the Literature, Meredith Hengy, Christina Artz, and Ben Friedman
44555 A National Cancer Database Analysis of Pleomorphic Dermal Sarcoma, Mustufa Jafry and Molly Powers
Evaluation of an SPF50 sunscreen containing photolyase and antioxidants for its antiphotoaging properties, Jessica Kern, Emily Wood, Rawaa Almukhtar, Kunal Angra, Michael Lipp, and Mitchel Goldman
PCR234 Impact of Draining Tunnels on Patient- and Physician-Reported Burden in Patients with Hidradenitis Suppurativa (HS), J. Kirby, Iltefat Hamzavi, A. P. Villani, R. B. Warren, A. Keal, A. C. Hernandez-Daly, R. Jha, H. Song, and A. B. Kimball
43533 Virtual dermoscopy course series in the improvement of resident education, Dayoung Ko, Christina Artz, and Laurie Kohen
Virtual dermoscopy course series in the improvement of resident education, Dayoung Ko, Christina Artz, and Laurie Kohen
42231 Trends In Price for Topical Corticosteroids from 2017-2021 and the Opportunity for Cost Savings Identifiable at the Point of Care: a Retrospective Study, Michael Kwa, Alexandra Guttentag, Lauren Chase, Jeroen van Meijgaard, and Henry W. Lim
41574 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Psoriasis Area and Severity Index Score by Body Region for the PSOARING 1 and 2 Trials, Alison M. Layton, Andrea Alexis, Hilary Baldwin, and Vincenzo Bettoli
41942 Improving Acne Care Recommendations From Personalising Acne: Consensus Of Experts (PACE), Alison M. Layton, Andrew Alexis, Hilary Baldwin, and Vincenzo Bettoli
Durability of efficacy and safety of roflumilast cream 0.3% in adults with chronic plaque psoriasis from a 52-Week, Phase 2 open-label safety trial, M. Lebwohl, Linda F. Stein Gold, M. J. Gooderham, K. A. Papp, L. K. Ferris, D. N. Adam, H. C. Hong, L. H. Kircik, M. Zirwas, P. Burnett, R. Higham, D. Krupa, and D. Berk
533 Mpox first skin lesion location: A reflection of mode of transmission?, J. E. Lubov, A. G. Strahan, S. Prasad, C. G. Casas, G. Hruza, Henry W. Lim, L. E. French, and E. Freeman
40666 Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet's Syndrome, Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, and Andrea Flower
44180 Influence of Baseline Disease Severity Defined by Investigator's Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study, Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, and Andrea Flower
Impact of Psoriasis in Special Areas on Patient Quality-of-Life Outcomes: Findings From the UPLIFT Survey in the United States, Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda F. Stein Gold, Andrea Flower, Shauna Jardon, Cynthia Deignan, and Mark Lebwohl
42166 Impact of Psoriasis in Special Areas on Patient Quality-of-Life Outcomes: Findings From the UPLIFT Survey in the United States, Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda F. Stein Gold, Andrea Flower, Shauna Jardon, Cynthia Deignan, and Mark G. Lebwohl
40528 Administration of bortezomib in patients with refractory scleromyxedema: A case report, Austin Mueller, Michael Kwa, and Holly Kerr
43451 Identifying patient characteristics that contribute to a successful scalp cooling experience: a mixed methods study, Madison Novice, Taylor Novice, Natalie Guzman, Joshua Goyert, Thomas Hester, Melissa Dejonckheere, Justine Wu, and Jacqueline Jeruss
Sun exposure and associated risks in 17 countries: UK results, Thierry Passeron, Brigitte Dreno, Susana Puig, Chee L. Goh, Henry W. Lim, Fatimata Ly, Hee Y. Kang, and Akimichi Morita
43772 Sk(in depth): staying up-to-date with the latest dermatology research, Catherine Reilly, Raquel Hoopes, Nicole Trupiano, Kelly Young, Jenna Yousif, and Taylor Novice
42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up), Jonathan I. Silverberg, Mette Deleuran, Linda F. Stein Gold, Christopher G. Bunick, Dirk J. Hijnen, Brian M. Calimlim, Henrique D. Teixeira, and Andrew Middle Platt
Comparison of investigator global assessment (IGA) and patient's global assessment (ptGA) of acne vulgaris among patients with moderate-to-severe non-nodular acne vulgaris (AV) administered sarecycline in community practices across the US: Analysis of PROSES study results, Linda F. Stein Gold, Andrew F. Alexis, Julie C. Harper, Emmy Graber, Hilary Baldwin, Leon Kircik, James Del Rosso, Richard G. Fried, Evan A. Rieder, Adelaide Hebert, Siva Narayanan, Volker Koscielny, and Ismail Kasujee
40660 Clinically Meaningful Improvement on the Acne Quality of Life Following Treatment with IDP- 126 Gel for Moderate-to-Severe Acne: A Post Hoc Exploratory Pooled Analysis of Phase III Trial Data, Linda F. Stein Gold, Ankur A. Dashputre, May Kamleh, Danellys Borroto, Tina Lin, Gale Harding, and George Joseph
43374 Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne, Linda F. Stein Gold, Alexandra Golant, Rocco Serrao, Anna M. Tallman, and Philip M. Brown
Tapinarof cream 1% once daily for plaque psoriasis: improvements in quality of life and clinical efficacy in two pivotal Phase 3 trials, Linda F. Stein Gold, Christopher E. M Griffiths, Anna M. Tallman, Philip M. Brown, and Mark G. Lebwohl
Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized Phase 2 and Phase 3 studies of the first triple combination drug, Linda F. Stein Gold, Leon H. Kircik, Emil A. Tanghetti, Hilary Baldwin, Zoe D. Draelos, Michael Gold, Edward Lain, David M. Pariser, Neil Sadick, Radhakrishnan Pillai, and Varsha Bhatt
Tapinarof Cream 1% Once Daily for Plaque Psoriasis in Two Pivotal Phase 3 Trials: Minimal Systemic Exposure is Consistent With Adverse Event Profile, Linda F. Stein Gold, Mark G. Lebwohl, Philip M. Brown, David S. Rubenstein, Glenn Tabolt, John E. Jett, and Stephen C. Piscitelli
441 Mpox in persons living with HIV: Results from an international dermatologic registry, A. G. Strahan, J. E. Lubov, S. Prasad, C. G. Casas, G. Hruza, Henry W. Lim, L. E. French, and E. Freeman
Impact of secukinumab on the need for rescue surgical intervention in patients with moderate to severe hidradenitis suppurativa: Post-hoc analysis of week 16 data from sunshine and sunrise trials, Hessel H. Van der Zee, Jacek C. Szepietowski, Christopher Sayed, Philippe Guillem, Iltefat H. Hamzavi, Stephanie Goldberg, Clarice Field, Christine-Elke Ortmann, Iryna Lobach, Magdalena B. Wozniak, Angela Llobet-Martinez, Shoba Ravichandran, Teresa Bachhuber, and Falk G. Bechara
Efficacy and safety of lebrikizumab at 16 weeks: Pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis, Richard B. Warren, Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D. Irvine, Linda F. Stein Gold, Andrew Blauvelt, and Eric L. Simpson
EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16, Andreas Wollenberg, Richard B. Warren, Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D. Irvine, Linda F. Stein Gold, and Andrew Blauvelt
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active nonsegmental vitiligo: results from a phase 2b, randomized, placebocontrolled, dose-ranging study, Yuji Yamaguchi, Elena Peeva, Ronald Shore, George Han, Lori A. Cox, Anindita Banerjee, Diamant Thaci, Iltefat Hamzavi, Abigail Sloan, Anand K. Ganesan, and Khaled Ezzedine
Submissions from 2022
EVALUATION of 1064/650NM PICOSECOND LASER SYSTEM EFFICACY for REDUCTION of PERI-ORBITAL HYPERPIGMENTATION, Rawaa Almukhtar, Emily S. Carr, Douglas Wu, and Mitchel P. Goldman
34631 Do patients with vitiligo and health care professionals treating them recognize the burden in living with the disease in the United States? Findings from the VALIANT study, Kristen Bibeau, John E. Harris, Iltefat H. Hamzavi, Anouk Lindley, Christine LaFiura, and Khaled Ezzedine
Clinical Outcomes Associated With Melanocytic Lesions Assessed Via Ancillary Gene Expression Profiling (GEP), Wyatt Boothby-Shoemaker, Brittani Jones, Linna L. Guan, and Ben J. Friedman
32388 Demographic and socioeconomic factors drive disparate outcomes in mycosis fungoides, Connor R. Buechler, Ethan Sagher, and Aaron Tisack
32329 Assessing the utility of Fontana-Masson and MART-1 stains in evaluating skin pigmentary changes induced by ultraviolet radiation and visible light, Marissa Ceresnie, Indermeet Kohli, Ben J. Friedman, Henry W. Lim, and Iltefat H. Hamzavi
617 The impact of the spectral composition of long-wavelength ultraviolet A1 and visible light on cutaneous biologic effects, Marissa Ceresnie, Jalal Maghfour, K El Dairi, Iltefat H. Hamzavi, Henry W. Lim, and Indermeet Kohli
CLINICAL APPLICATIONS of LASERS in TRANSGENDER MEDICINE, Marissa S. Ceresnie, Brittani Jones, Jalal Maghfour, and David M. Ozog
Management of truncal acne with oral sarecycline: pooled results from two Phase 3 clinical trials, James Q. Del Rosso, Linda F. Stein Gold, Hilary Baldwin, Julie C. Harper, Joshua Zeichner, Sabine Obagi, Emmy Graber, and Xochitl Jimenez
542 Murine epidermis harbors functionally distinct langerhans cell subsets, Peter Dimitrion, Indra Adrianto, Yi Yao, Michael Pawlitz, Ian Loveless, and Hongmei Peng
34794 Long-term safety and disease control of ruxolitinib cream among Black or African American patients with atopic dermatitis: Pooled results from 2 phase 3 studies, Lawrence F. Eichenfield, Linda F. Stein Gold, Zelma C. Chiesa Fuxench, May E. Venturanza, Haobo Ren, and Kanwaljit K. Brar
275 Effects of ruxolitinib cream on sleep and quality of life over 52 weeks in black patients with atopic dermatitis, L. F. Eichenfield, Linda F. Stein Gold, K. K. Brar, Z. C. Chiesa Fuxench, J. I. Silverberg, M. E. Venturanza, H. Kallender, J. Gao, and E. Simpson
287 Effects of ruxolitinib cream on pruritus in black patients with atopic dermatitis, L. F. Eichenfield, Linda F. Stein Gold, K. K. Brar, Z. C. Chiesa Fuxench, J. I. Silverberg, M. E. Venturanza, H. Kallender, J. Gao, and J. C. Szepietowski
367 Googling acne: Analyzing ingredients and price of over the counter acne products, Kareem Elhage, Jonah Yousif, Michael Kwa, and Linda F. Stein Gold
33714 Palisaded neutrophilic and granulomatous dermatitis in the setting of SRSF2-mutated chronic myelomonocytic leukemia: Case report and review of the literature, Christina D. Enescu, Avni Patel, and Ben J. Friedman
Updates on the hidradenitis suppurativa from the USA, Iltefat H. Hamzavi
34612 Exploring the natural history of vitiligo in the United States: Findings from the VALIANT study, John E. Harris, Kristen Bibeau, Iltefat H. Hamzavi, Pearl Grimes, Anouk Lindley, Christine LaFiura, and Khaled Ezzedine
35224 Identifying a correlation between preceding trauma and development of dermatofibrosarcoma protuberans: A review of the literature, Brittani Jones, Jesse Veenstra, and David M. Ozog
633 Comparison of soluble proteins from skin sections of acne and TCA induced postinflammatory hyperpigmentation and erythema, N. Karaman-Jurukovska, Iltefat H. Hamzavi, Indermeet Kohli, C. Nicholson, and Tasneem F. Mohammad
Roflumilast cream significantly improves patient burden and work productivity in patients with psoriasis, Leon H. Kircik, Lorne Albrecht, Laura K. Ferris, Melinda Gooderham, H. Chih-ho Hong, Steven E. Kempers, Mark G. Lebwohl, and Vandana K. Madkan
34441 Keratoderma blenorrhagicum and balanitis circinata: Indicators of reactive arthritis, Dayoung Ko, Meredith Hengy, and Chauncey A. McHargue
623 Variations in in vivo visible light phototesting methodologies, Indermeet Kohli
35360 Recalcitrant pediatric bullous erythema multiforme responsive to oral tofacitinib, Sasank Konda, Nayha Shetty, and Jesse Y. Liu
Safety and efficacy of once-daily roflumilast cream 0.3%, a potent phosphodiesterase-4 inhibitor, for the treatment of psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 trials, Mark G. Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda F. Stein Gold, James Del Rosso, Zoe D. Draelos, Melinda G. Gooderham, and Lawrence J. Green
31064 The Detroit Keloid Scale: A validated tool for rating keloids, Alexis B. Lyons, David M. Ozog, Henry W. Lim, Kate V. Viola, Lamont R. Jones, and Amy Tang
396 Characterizing inpatient hospitalizations for hidradenitis suppurativa and assessing the impact of outpatient dermatology care on hospitalizations, Jalal Maghfour, Vivian Liu, and Richard H. Huggins
35186 Exploring the association between frontal fibrosing alopecia sunscreen and moisturizers, Jalal Maghfour and Joshua Olson
33396 Nonuremic calciphylaxis precipitated by COVID 19 infection, Nathaniel Messenger, Christina Artz, and Pranita V. Rambhatla
33778 The impact and implications of COVID-19 on using scalp cooling therapy for prevention of chemotherapy-induced alopecia, Taylor Novice, Madison Novice, Katerina Svigos, Molly Powers, and Kristen Lo Sicco
34722 Nail-patella syndrome: An early dermatologic diagnosis, Sandra Oska, Kelly Kennelly, and Vinod Misra
32622 Imaging technologies for presurgical margin assessment of basal cell carcinoma, Krishan Parashar, Angeli E. Torres, and Wyatt T. Boothby-Shoemaker
A pooled analysis of randomized, controlled, Phase 3 trials investigating the efficacy and safety of a novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis, Andreas Pinter, Lawrence J. Green, Johan Selmer, Morten Praestegaard, Linda F. Stein Gold, and Matthias Augustin
168 COVID-19 mRNA vaccine booster cutaneous reactions reported to the AAD/ILDS dermatology registry, S. Prasad, D. E. McMahon, A. Tyagi, R. Singh, R. Ali, Henry W. Lim, L. P. Fox, K. Blumenthal, G. Hruza, L. E. French, and E. Freeman
32131 Updating the relative risk of ultraviolet exposure and melanoma in fair skin types: A systematic review, Manisha Ravi, Michael Kwa, Kriti Babu, and Henry W. Lim
Differences in patient and dermatologist perspectives on psoriasis treatment: results from the UPLIFT survey, Kristian Reich, Paolo Gisondi, Linda F. Stein Gold, Peter van de Kerkhof, Richard Langley, Carle Paul, Lluis Puig, and Hideshi Torii
